ReviewFrontiers in neurology2025
Fatigue and neuropsychiatric symptoms in Parkinson's disease: a narrative review.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parkinson's disease beyond motor symptoms: a review of the validity and limitations of current classification of non-motor symptoms.Frontiers in psychiatry · 2026Review
- Directional Symptom Dependencies in Multiple Sclerosis and Parkinson's Disease: A Comparative Bayesian Network Analysis.Journal of multidisciplinary healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatigue in Parkinson's disease (PD) is a highly prevalent and disabling non-motor symptom, often manifesting early and worsening over the disease course. Despite its significant impact on quality of life, fatigue remains underrecognized and poorly managed in clinical practice. It is a complex, multidimensional syndrome encompassing cognitive, emotional, and physical components. Its pathophysiology is multifactorial, involving disrupted dopaminergic, serotonergic, and glutamatergic signaling across fronto-striatal and limbic circuits. Fatigue frequently overlaps with neuropsychiatric symptoms such as apathy, depression, anxiety, and cognitive impairment, complicating both diagnosis and treatment. Although these conditions are clinically distinct, they share overlapping neural substrates and may influence each other's presentation and severity. Currently available therapeutic options for PD-related fatigue are limited, with rasagiline considered only "possibly useful," and most other pharmacologic and non-pharmacological strategies lacking rigorous evidence. This narrative review is based on a non-systematic PubMed literature search of peer-reviewed articles in English up to April 2025, with additional relevant studies identified through reference lists. It examines the clinical and neurobiological intersections between fatigue and neuropsychiatric symptoms in PD, highlighting key diagnostic challenges, treatment limitations, and future directions. Standardizing terminology, dissecting fatigue from overlapping neuropsychiatric symptoms, identifying reliable biomarkers, and conducting well-designed, mechanism-based clinical trials are essential next steps to redefine fatigue as a measurable and treatable symptom in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.